Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-kappaB deinhibition. It can be u
CAS Number:
[1000676-41-4]
Target:
IPH2102 , ONO-4483
* VAT and and shipping costs not included. Errors and price changes excepted